CL2020000483A1 - Nuevos usos de derivados de piperidinil–indol. - Google Patents

Nuevos usos de derivados de piperidinil–indol.

Info

Publication number
CL2020000483A1
CL2020000483A1 CL2020000483A CL2020000483A CL2020000483A1 CL 2020000483 A1 CL2020000483 A1 CL 2020000483A1 CL 2020000483 A CL2020000483 A CL 2020000483A CL 2020000483 A CL2020000483 A CL 2020000483A CL 2020000483 A1 CL2020000483 A1 CL 2020000483A1
Authority
CL
Chile
Prior art keywords
piperidinyl
indole derivatives
new uses
glomerulopathy
treatment
Prior art date
Application number
CL2020000483A
Other languages
English (en)
Inventor
Jörg Eder
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020000483A1 publication Critical patent/CL2020000483A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL USO NOVEDOSO DE CIERTOS DERIVADOS DE PIPERIDINIL– INDOL EN EL TRATAMIENTO DE PACIENTES QUE PADECEN ENFERMEDADES O TRASTORNOS RENALES, Y EN PARTICULAR, PARA EL TRATAMIENTO DE PACIENTES QUE PADECEN C3G (GLOMERULOPATÍA C3) E IGAN (NEFROPATÍA POR IGA).
CL2020000483A 2017-08-31 2020-02-27 Nuevos usos de derivados de piperidinil–indol. CL2020000483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31

Publications (1)

Publication Number Publication Date
CL2020000483A1 true CL2020000483A1 (es) 2020-09-04

Family

ID=59745840

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000483A CL2020000483A1 (es) 2017-08-31 2020-02-27 Nuevos usos de derivados de piperidinil–indol.

Country Status (12)

Country Link
US (2) US11723901B2 (es)
EP (2) EP4393545A3 (es)
JP (3) JP6754919B1 (es)
KR (3) KR102682887B1 (es)
CN (5) CN117398384A (es)
AU (1) AU2018326768B2 (es)
BR (1) BR112020003737A2 (es)
CA (1) CA3073346A1 (es)
CL (1) CL2020000483A1 (es)
IL (1) IL272888B2 (es)
MX (3) MX2020002185A (es)
WO (1) WO2019043609A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021125313A1 (ja) * 2019-12-19 2021-06-24 大鵬薬品工業株式会社 縮合ピリミジン化合物を有効成分とする治療剤
CN115667240A (zh) 2020-05-18 2023-01-31 诺华股份有限公司 Lnp023的结晶形式
US20230331710A1 (en) * 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
KR20230049115A (ko) 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
AU2021414185A1 (en) * 2020-12-30 2023-08-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof
CN117479937A (zh) * 2021-05-07 2024-01-30 诺华股份有限公司 用于治疗非典型溶血性尿毒综合征的伊普可泮
AU2022329230A1 (en) * 2021-08-18 2024-03-21 Xizang Haisco Pharmaceutical Co., Ltd. Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
MX2024004921A (es) * 2021-10-27 2024-06-19 Hansoh Bio Llc Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
WO2023139534A1 (en) * 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2023143293A1 (zh) * 2022-01-26 2023-08-03 上海美悦生物科技发展有限公司 补体因子b抑制剂的盐型、晶型及其制备方法和应用
WO2023237041A1 (zh) * 2022-06-10 2023-12-14 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2024002353A1 (zh) * 2022-06-30 2024-01-04 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法
WO2024051849A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
CN118026998A (zh) * 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
EP2867227B1 (en) * 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EP3394089B1 (en) * 2015-12-23 2021-07-28 eleva GmbH Polypeptides for inhibiting complement activation

Also Published As

Publication number Publication date
MX2020002185A (es) 2020-07-14
BR112020003737A2 (pt) 2020-09-01
EP4393545A2 (en) 2024-07-03
JP2021181471A (ja) 2021-11-25
RU2020111788A3 (es) 2021-12-28
AU2018326768B2 (en) 2021-07-29
US11723901B2 (en) 2023-08-15
CN117338781A (zh) 2024-01-05
JP2020529466A (ja) 2020-10-08
EP4393545A3 (en) 2024-09-25
CN111032042A (zh) 2020-04-17
MX2023010751A (es) 2023-09-20
RU2020111788A (ru) 2021-09-30
WO2019043609A1 (en) 2019-03-07
IL272888B2 (en) 2024-01-01
CN117338783A (zh) 2024-01-05
IL272888B1 (en) 2023-09-01
KR20230024432A (ko) 2023-02-20
JP6754919B1 (ja) 2020-09-16
JP2020193222A (ja) 2020-12-03
MX2023010750A (es) 2023-09-20
JP7297016B2 (ja) 2023-06-23
KR20240111007A (ko) 2024-07-16
KR20200047540A (ko) 2020-05-07
AU2018326768A1 (en) 2020-02-06
CN117398384A (zh) 2024-01-16
IL272888A (en) 2020-04-30
KR102497487B1 (ko) 2023-02-08
EP3675854A1 (en) 2020-07-08
JP6929425B2 (ja) 2021-09-01
US20220152011A1 (en) 2022-05-19
CN117338782A (zh) 2024-01-05
US20200338059A1 (en) 2020-10-29
CA3073346A1 (en) 2019-03-07
KR102682887B1 (ko) 2024-07-08

Similar Documents

Publication Publication Date Title
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CY1121360T1 (el) Αναστολεις dna-pk
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2020001167A1 (es) Moduladores de la vía de estrés integrada
UY37230A (es) Moduladores de la vía de estrés integrada
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
CO2020006227A2 (es) Moduladores de la vía de estrés integrada
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX2020004558A (es) Moduladores de la vía de estrés integrada.
MX2020004557A (es) Moduladores de la vía de estrés integrada.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CO6551721A2 (es) Moduladores de cinasa novedosos
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CL2019000702A1 (es) Anticuerpos anti-gm-csf y usos de los mismos.
CL2021000930A1 (es) Piridazinas novedosas
CO2017013361A2 (es) Angiogénesis usando células madre placentarias estimuladas
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares